Cynata Therapeutics Limited announced the appointment of Dr. Kilian Kelly to the position of Managing Director and Director, effective 1 July 2023, following the retirement of Dr. Ross Macdonald. Dr. Kelly has been Cynata's Chief Operating Officer since May 2019 and has been instrumental in advancing the Company's clinical pipeline since joining Cynata as Vice President, Product Development in 2014. The company is also pleased to welcome Dr. David Atkins to the Board of Directors.

Dr. Atkins is the Managing Partner of BioScience Managers, an international healthcare investment firm and a major Cynata shareholder. Dr. Stewart Washer will step down from his position as a non-executive director. Dr. Atkins has over 25 years' experience as a global leader in a broad range of life science and healthcare businesses including Johnson & Johnson and Danaher.

He has held senior leadership positions in R&D, business development, operations and sales and marketing. David has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Furthermore, David has founded or assumed leadership roles in 3 start-up businesses in gene therapy, molecular and cellular cancer diagnostics and clinical genomics.

Given Dr. Atkins' executive role with Bioscience Managers (a substantial holder of Cynata), the Board considers that Dr. Atkins is not an independent director.